Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: Architecture and outcomes

Anticancer Research

Volumn 32, Issue 6, 2012, Pages 2377-2383

  Shirasu, Naoto ^a   Kuroki, Masahide ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Adoptive immunotherapy; Chimeric antigen receptor (CAR); Gene therapy; Review

Indexed keywords

T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; ANTINEOPLASTIC AGENT; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTATION; ANTIGENICITY; CANCER IMMUNOTHERAPY; HUMAN; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; ANIMAL; CHEMISTRY; IMMUNOLOGY; METHODOLOGY; NEOPLASM; SYNTHESIS; T LYMPHOCYTE; TRANSPLANTATION;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84864567175     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Paul S, Calmels B and Acres R: Improvement of adoptive cellular immunotherapy of human cancer using ex vivo gene transfer. Curr Gene Ther 2: 91-100, 2002.
2. Yamasaki A, Onishi H, Morisaki T and Katano M: Induction of cytotoxic T-lymphocytes by CEA peptide-pulsed gdT-cells isolated from patients with advanced cancer. Anticancer Res 31: 2419-2424, 2011.
3. Ngo MC, Rooney CM, Howard JM and Heslop HE: Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Hum Mol Genet 20: R93-99, 2011.
4. Vanderlinden K, Wilgenhof S, Van De Winkel N, Geers C, Thielemans K, Neyns B, De Vogelaere K and Delvaux G: Long-term disease-free survival following dendritic cell therapy and resection of small bowel melanoma metastases - a case report. Anticancer Res 31: 3579-3583, 2011.
5. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE and Rosenberg SA: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26: 5233-5239, 2008.
6. Rosenberg SA, Restifo NP, Yang JC, Morgan RA and Dudley ME: Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8: 299-308, 2008.
7. Zou J, Nagarkatti P, Zhong Y and Nagarkatti M: Characterization of T-cell memory phenotype after in vitro expansion of tumor-infiltrating lymphocytes from melanoma patients. Anticancer Res 31: 4099-4109, 2011.
8. Ryu K, Lee Y, Kim B, Park Y, Kim Y, Hur S, Kim T, Kim I and Kim J: Alterations of HLA class I and II antigen expression in preinvasive, invasive and metastatic cervical cancers. Exp Mol Med 33: 136-144, 2001.
9. Ferris R, Hunt J and Ferrone S: Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res 33: 113-133, 2005.
10. Sadelain M, Brentjens R and Riviere I: The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 21: 215-223, 2009.
11. Mezzanzanica D, Canevari S, Mazzoni A, Figini M, Colnaghi MI, Waks T, Schindler DG and Eshhar Z: Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T-cells. Cancer Gene Ther 5: 401-407, 1998.
12. Westwood JA, Smyth MJ, Teng MW, Moeller M, Trapani JA, Scott AM, Smyth FE, Cartwright GA, Power BE, Hönemann D, Prince HM, Darcy PK and Kershaw MH: Adoptive transfer of T-cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci USA 102: 19051-19056, 2005.
13. Niederman TM, Ghogawala Z, Carter BS, Tompkins HS, Russell MM and Mulligan RC: Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci USA 99: 7009-7014, 2002.
14. Pameijer CR, Navanjo A, Meechoovet B, Wagner JR, Aguilar B, Wright CL, Chang WC, Brown CE and Jensen MC: Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T-cell antigen receptor. Cancer Gene Ther 14: 91-97, 2006.
15. Muniappan A, Banapour B, Lebkowski J and Talib S: Ligand-mediated cytolysis of tumor cells: use of heregulin-zeta chimeras to redirect cytotoxic T-lymphocytes. Cancer Gene Ther 7: 128-134, 2000.
16. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ and Jensen MC: Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine re-directed cytolytic T-cells. Cancer Res 64: 9160-9166, 2004.
17. Barber A, Zhang T and Sentman CL: Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. J Immunol 180: 72-78, 2008.
18. Zhang T, Barber A and Sentman CL: Chimeric NKG2D-modified T-cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. Cancer Res 67: 11029-11036, 2007.
19. Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S, Yu J, Scholler N and Powell DJ Jr.: A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res 72: 1844-1852, 2012.
20. Turatti F, Figini M, Balladore E, Alberti P, Casalini P, Marks JD, Canevari S and Mezzanzanica D: Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J Immunother 30: 684-693, 2007.
21. Chmielewski M, Hombach A, Heuser C, Adams GP and Abken H: T-cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T-cell activation against antigen-positive target cells but decreases selectivity. J Immunol 173: 7647-7653, 2004.
22. Weijtens ME, Hart EH and Bolhuis RL: Functional balance between T-cell chimeric receptor density and tumor-associated antigen density: CTL-mediated cytolysis and lymphokine production. Gene Ther 7: 35-42, 2000.
23. Hombach AA, Schildgen V, Heuser C, Finnern R, Gilham DE and Abken H: T-cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of re-directed T-cells. J Immunol 178: 4650-4657, 2007.
24. Alvarez-Vallina L and Russell SJ: Efficient discrimination between different densities of target antigen by tetracycline-regulatable T bodies. Hum Gene Ther 10: 559-563, 1999.
25. Lamers CH, Willemsen R, van Elzakker P, van Steenbergen-Langeveld S, Broertjes M, Oosterwijk-Wakka J, Oosterwijk E, Sleijfer S, Debets R and Gratama JW: Immune responses to transgene and retroviral vector in patients treated with ex vivoengineered T-cells. Blood 117: 72-82, 2010.
26. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA and Hwu P: A phase I study on adoptive immunotherapy using gene-modified T-cells for ovarian cancer. Clin Cancer Res 12: 6106-6115, 2006.
27. Shibaguchi H, Luo NX, Kuroki M, Zhao J, Huang J, Hachimine K, Kinugasa T and Kuroki M: A fully human chimeric immune receptor for retargeting T-cells to CEA-expressing tumor cells. Anticancer Res 26: 4067-4072, 2006.
28. Shirasu N, Shibaguchi H, Kuroki M, Yamada H and Kuroki M: Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen. Anticancer Res 30: 2731-2738, 2010.
29. Moritz D and Groner B: A spacer region between the single chain antibody and the CD3 zeta-chain domain of chimeric T-cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther 2: 539-546, 1995.
30. Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O'Neill A, Irlam J, Chester KA, Kemshead JT, Shaw DM, Embleton MJ, Stern PL and Gilham DE: The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother 28: 203-211, 2005.
31. James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, Raubitschek AA, Forman SJ and Press OW: Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol 180: 7028-7038, 2008.
32. Accardi L and Di Bonito P: Antibodies in single-chain format against tumour-associated antigens: present and future applications. Curr Med Chem 17: 1730-1755, 2010.
33. Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M and Gilham DE: The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol 184: 6938-6949, 2010.
34. Shirasu N, Yamada H, Shibaguchi H, Kuroki M and Kuroki M: Molecular characterization of a fully human chimeric T-cell antigen receptor for tumor-associated antigen EpCAM. J Biomed Biotech in press: 2012.
35. Gross G, Gorochov G, Waks T and Eshhar Z: Generation of effector T-cells expressing chimeric T cell receptor with antibody type-specificity. Transplant Proc 21: 127-130, 1989.
36. Eshhar Z, Waks T, Gross G and Schindler DG: Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad USA 90: 720-724, 1993.
37. Bezbradica JS and Medzhitov R: Role of ITAM signaling module in signal integration. Curr Opin Immunol 24: 58-66, 2012.
38. Haynes NM, Snook MB, Trapani JA, Cerruti L, Jane SM, Smyth MJ and Darcy PK: Re-directing mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs. Fc epsilon RI-gamma. J Immunol 166: 182-187, 2001.
39. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, Quintás-Cardama A, Larson SM and Sadelain M: Genetically targeted T-cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 13: 5426-5435, 2007.
40. Brocker T: Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T-cells. Blood 96: 1999-2001, 2000.
41. Brocker T and Karjalainen K: Adoptive tumor immunity mediated by lymphocytes bearing modified antigen-specific receptors. Adv Immunol 68: 257-269, 1998.
42. Gong MC, Latouche J-B, Krause A, Heston W, Bander NH and Sadelain M: Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1: 123-127, 1999.
43. Lenschow DJ, Walunas TL and Bluestone JA: CD28/B7 system of T-cell co-stimulation. Annu Rev Immunol 14: 233-258, 1996.
44. Geiger TL, Nguyen P, Leitenberg D and Flavell RA: Integrated src kinase and co-stimulatory activity enhances signal transduction through single-chain chimeric receptors in T-lymphocytes. Blood 98: 2364-2371, 2001.
45. Hombach A, Heuser C, Marquardt T, Wieczarkowiecz A, Groneck V, Pohl C and Abken H: CD4+ T-cells engrafted with a recombinant immunoreceptor efficiently lyse target cells in a MHC antigen- and Fas-independent fashion. J Immunol 167: 1090-1096, 2001.
46. Maher J, Brentjens RJ, Gunset G, Rivière I and Sadelain M: Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR zeta/CD28 receptor. Nat Biotechnol 20: 70-75, 2002.
47. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ and Darcy PK: Single-chain antigen recognition receptors that co-stimulate potent rejection of established experimental tumors. Blood 100: 3155-3163, 2002.
48. Finney HM, Akbar AN and Lawson AD: Activation of resting human primary T-cells with chimeric receptors: co-stimulation from CD28, inducible co-stimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 172: 104-113, 2004.
49. Croft M: The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 9: 271-285, 2009.
50. Zang X and Allison JP: The B7 family and cancer therapy: co-stimulation and co-inhibition. Clin Cancer Res 13: 5271-5279, 2007.
51. Harada Y, Ohgai D, Watanabe R, Okano K, Koiwai O, Tanabe K, Toma H, Altman A and Abe R: A single amino acid alteration in cytoplasmic domain determines IL-2 promoter activation by ligation of CD28 but not inducible co-stimulator (ICOS). J Exp Med 197: 257-262, 2003.
52. Pulè MA, Straathof KC, Dotti G, Heslop HE, Rooney CM and Brenner MK: A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T-cells. Mol Ther 12: 933-941, 2005.
53. Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA and Morgan RA: A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T-lymphocytes and antitumor activity. J Immunol 183: 5563-5574, 2009.
54. Hombach A, Heiders J, Foppe M, Chmielewski M and Abken H: OX40 co-stimulation by a chimeric antigen receptor abrogates CD28- and IL-2-induced IL-10 secretion by re-directed CD4+ T-cells. Oncoimmunol 1: 460-468, 2012.
55. Park TS, Rosenberg SA and Morgan RA: Treating cancer with genetically engineered T-cells. Trends Biotechnol 29: 550-557, 2011.
56. Ertl HC, Zaia J, Rosenberg SA, June CH, Dotti G, Kahn J, Cooper LJ, Corrigan-Curay J and Strome SE: Considerations for the clinical application of chimeric antigen receptor T-cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. Cancer Res 71: 3175-3181, 2011.
57. Chicaybam L, Sodré AL and Bonamino M: Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions. Int Rev Immunol 30: 294-311, 2011.
58. Biagi E, Marin V, Attianese GM, Pizzitola I, Tettamanti S, Cribioli E and Biondi A: New advances in leukaemia immunotherapy by the use of chimeric artificial antigen receptors (CARs): state of the art and perspectives for the near future. Ital J Pediatr 37: 46-55, 2011.
59. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, VanWaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM and Rosenberg SA: Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114: 535-546, 2009.
60. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins PF, Laurencot CM and Rosenberg SA: T-cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19: 620-626, 2011.
61. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ, Gopal AK, Pagel JM, Lindgren CG, Greenberg PD, Riddell SR and Press OW: Adoptive immunotherapy for indolent non-Hodgkin's lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T-cells. Blood 112: 2261-2271, 2008.
62. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C and Rosenberg SA: Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29: 917-927, 2011.
63. Pulè MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE and Brenner MK: Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14: 1264-1270, 2008.
64. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A and June CH: T-cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3: 95ra73, 2011.
65. Porter DL, Levine BL, Kalos M, Bagg A and June CH: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733, 2011.
66. Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y, Pagel JM, Budde LE, Raubitschek A, Forman SJ, Greenberg PD, Riddell SR and Press OW: CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119: 3940-3950, 2012.
67. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM and Rosenberg SA: Case report of a serious adverse event following the administration of T-cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18: 843-851, 2010.
68. Cartellieri M, Bachmann M, Feldmann A, Bippes C, Stamova S, Wehner R, Temme A and Schmitz M: Chimeric antigen receptor-engineered T-cells for immunotherapy of cancer. J Biomed Biotechnol 2010: 956304, 2012.